Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 5:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2545–2568 of 8,193 matching trials from the live ClinicalTrials.gov search.
Conditions
Obsessive-Compulsive Disorder
Interventions
Troriluzole, Placebo
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
49
States / cities
Phoenix, Arizona • Culver City, California • La Jolla, California + 45 more
Conditions
Sleep Disorder
Interventions
ABT-652, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Phoenix, Arizona • Glendale, California • San Diego, California + 2 more
Conditions
Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma, Recurrent Extrapulmonary Neuroendocrine Carcinoma, Unresectable Extrapulmonary Neuroendocrine Carcinoma
Interventions
Atezolizumab, Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Etoposide, Magnetic Resonance Imaging, Patient Observation
Biological · Procedure · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
267
States / cities
Anchorage, Alaska • Phoenix, Arizona • Anaheim, California + 201 more
Conditions
BRAF V600E-mutant Metastatic Colorectal Cancer
Interventions
Encorafenib, Binimetinib, Cetuximab, Irinotecan, Folinic Acid, 5-Fluorouracil
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
90
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 45 more
Conditions
Vulvovaginal Atrophy, Menopause, Dyspareunia, Painful Intercourse
Interventions
Estradiol, Placebo
Drug
Lead sponsor
TherapeuticsMD
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
764 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
100
States / cities
Huntsville, Alabama • Montgomery, Alabama • Mesa, Arizona + 85 more
Conditions
Constipation, Chronic Constipation
Interventions
A3309
Drug
Lead sponsor
Albireo
Industry
Eligibility
20 Years to 80 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
44
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 40 more
Active, not recruiting Not applicable Interventional

ASCEND CSP IDE Study

NCT06830746
Conditions
Heart Failure, Ventricular Arrythmia
Interventions
LBBAP Implant with a CSP ICD Lead
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 99 Years
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
16
States / cities
Huntsville, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 13 more
Conditions
Lichen Planopilaris
Interventions
Oral Brepocitinib, Placebo
Drug
Lead sponsor
Priovant Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 42 more
Conditions
Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma
Interventions
Aldoxorubicin, Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
15 Years and older
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 30 more
Conditions
HIV Infections
Interventions
Indinavir sulfate, Levocarnitine, Adefovir dipivoxil, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
14
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more
Conditions
Breast Adenocarcinoma, HER2 Positive Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7
Interventions
Aromatase Inhibition Therapy, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Tamoxifen Citrate, Trastuzumab
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
3,436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
154
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 119 more
Conditions
Prostate Cancer
Interventions
MyProstateScore
Diagnostic Test
Lead sponsor
LynxDx
Industry
Eligibility
45 Years and older · Male only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Phoenix, Arizona
Completed Phase 2 Interventional Results available

A Study of CCX140-B in Subjects With FSGS

NCT03536754
Conditions
FSGS, Focal Segmental Glomerulosclerosis, Glomerulosclerosis
Interventions
Placebo, CCX140-B
Other · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Phoenix, Arizona • Torrance, California • Shreveport, Louisiana + 6 more
Conditions
Symptomatic Neurogenic Orthostatic Hypotension
Interventions
Droxidopa capsules, Placebo capsules
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years and older
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
168
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 103 more
Conditions
Acute Ischemic Stroke
Interventions
Neuro-vascular access
Device
Lead sponsor
Medtronic Neurovascular Clinical Affairs
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
9
States / cities
Phoenix, Arizona • Englewood, Colorado • Jacksonville, Florida + 6 more
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
nuzefatide pevedotin (BT5528)
Drug
Lead sponsor
BicycleTx Limited
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 3 more
Conditions
Intracerebral Hemorrhage, Atrial Fibrillation
Interventions
Apixaban, Aspirin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
186
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 141 more
Conditions
Oral Mucositis
Interventions
SCV-07, Placebo
Drug
Lead sponsor
SciClone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
49
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 45 more
Active, not recruiting Not applicable Interventional

Pilot/Pivotal Study of DBS+Rehab After Stroke

NCT05701280
Conditions
Stroke, Upper Extremity Paresis
Interventions
Deep Brain Stimulation, Rehabilitation
Device · Other
Lead sponsor
Enspire DBS Therapy, Inc.
Industry
Eligibility
21 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
9
States / cities
Phoenix, Arizona • Baltimore, Maryland • Boston, Massachusetts + 6 more
Conditions
Asthma
Interventions
GW685698X
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
627 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
94
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 82 more
Conditions
Type 2 Diabetes Mellitus
Interventions
Exenatide SC, Exenatide IV, Placebo SC, Exendin-9, Placebo IV
Drug
Lead sponsor
Carl T. Hayden VA Medical Center
Federal
Eligibility
35 Years to 70 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Chronic Cough
Interventions
S-600918, Placebo to S-600918
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
51
States / cities
Litchfield Park, Arizona • Phoenix, Arizona • Tempe, Arizona + 40 more
Conditions
Colorectal Cancer
Interventions
ethynyluracil, fluorouracil
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
86
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more
Conditions
Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Chest Radiography, Cisplatin, Computed Tomography, Echocardiography Test, Electronic Health Record Review, Fluciclovine F18, Gemcitabine, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, X-Ray Imaging
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
76
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 67 more